By Helgi Analytics - September 29, 2020
Pilulka made a net profit of CZK -58.5 mil with revenues of CZK 1,321 mil in 2019, down by 39.7% and up by 27.8%, r...
By Helgi Analytics - September 29, 2020
Pilulka stock traded at CZK 900 per share at the end 2019 translating into a market capitalization of USD 40.1 mil. Since the end...
By Helgi Analytics - September 29, 2020
Pilulka made a net profit of CZK -58.5 mil in 2019, down 39.7% compared to the previous year. Historically, between 2018 and...
Profit Statement | 2022 | 2023 | 2024 | |
Sales | 2,679 | 3,378 | 4,267 | |
Gross Profit | CZK mil | 734 | 936 | 1,192 |
EBITDA | 49.8 | 93.1 | 147 | |
EBIT | 11.0 | 44.6 | 86.6 | |
Financing Cost | CZK mil | 2.91 | 3.61 | 4.31 |
Pre-Tax Profit | CZK mil | 8.12 | 41.0 | 82.3 |
Net Profit | CZK mil | 8.12 | 41.0 | 82.3 |
Dividends | CZK mil | 0 | 0 | 0 |
Balance Sheet | 2022 | 2023 | 2024 | |
Total Assets | CZK mil | 650 | 788 | 989 |
Non-Current Assets | CZK mil | 152 | 173 | 190 |
Current Assets | CZK mil | 498 | 615 | 800 |
Working Capital | CZK mil | -15.3 | 4.04 | 18.8 |
Shareholders' Equity | CZK mil | 186 | 222 | 295 |
Liabilities | CZK mil | 464 | 566 | 694 |
Total Debt | CZK mil | 104 | 129 | 154 |
Net Debt | CZK mil | -9.85 | -10.6 | -60.8 |
Ratios | 2022 | 2023 | 2024 | |
ROE | % | 5.88 | 21.2 | 31.8 |
ROCE | % | 6.42 | 26.1 | 42.6 |
Gross Margin | % | 27.4 | 27.7 | 27.9 |
EBITDA Margin | % | 1.86 | 2.76 | 3.44 |
EBIT Margin | % | 0.412 | 1.32 | 2.03 |
Net Margin | % | 0.303 | 1.21 | 1.93 |
Net Debt/EBITDA | -0.198 | -0.114 | -0.414 | |
Net Debt/Equity | % | -5.30 | -4.78 | -20.6 |
Cost of Financing | % | 3.06 | 3.10 | 3.05 |
Valuation | 2022 | 2023 | 2024 | |
Market Capitalisation | USD mil | 40.1 | 40.1 | 40.1 |
Enterprise Value (EV) | USD mil | 39.6 | 39.6 | 37.4 |
Number Of Shares | mil | 1.00 | 1.00 | 1.00 |
Share Price | CZK | 900 | 900 | 900 |
EV/EBITDA | 17.4 | 9.31 | 5.56 | |
EV/Sales | 0.324 | 0.256 | 0.192 | |
Price/Earnings (P/E) | 91.1 | 22.5 | 11.5 | |
Price/Book Value (P/BV) | 4.84 | 4.06 | 3.05 | |
Dividend Yield | % | 0 | 0 | 0 |
Get all company financials in excel:
overview | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
income statement | ||||||||
Sales | 1,033 | |||||||
Gross Profit | CZK mil | 267 | ||||||
EBIT | -40.8 | |||||||
Net Profit | CZK mil | -41.9 | ||||||
ROE | % | ... | ||||||
EBIT Margin | % | -3.95 | ||||||
Net Margin | % | -4.06 | ||||||
Employees | 217 | ... | ... | ... | ... | |||
balance sheet | ||||||||
Total Assets | CZK mil | 306 | ||||||
Non-Current Assets | CZK mil | 68.3 | ||||||
Current Assets | CZK mil | 238 | ||||||
Shareholders' Equity | CZK mil | 15.8 | ||||||
Liabilities | CZK mil | 290 | ||||||
Non-Current Liabilities | CZK mil | 31.4 | ||||||
Current Liabilities | CZK mil | 259 | ||||||
Net Debt/EBITDA | -2.64 | |||||||
Net Debt/Equity | % | 484 | ||||||
Cost of Financing | % | ... | ||||||
cash flow | ||||||||
Total Cash From Operations | CZK mil | -13.4 | ||||||
Total Cash From Investing | CZK mil | -37.1 | ||||||
Total Cash From Financing | CZK mil | 42.5 | ||||||
Net Change In Cash | CZK mil | -8.05 | ||||||
valuation | ||||||||
Market Capitalisation | USD mil | 40.1 | ||||||
Enterprise Value (EV) | USD mil | 43.5 | ||||||
Number Of Shares | mil | 1.00 | ||||||
Share Price | CZK | 900 | ||||||
Price/Earnings (P/E) | ... | |||||||
Price/Cash Earnings (P/CE) | -30.0 | |||||||
EV/EBITDA | -32.9 | |||||||
Price/Book Value (P/BV) | 57.1 | |||||||
Dividend Yield | % | 0 |
income statement | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
income statement | ||||||||
Sales | 1,033 | |||||||
Cost of Goods & Services | CZK mil | 766 | ||||||
Gross Profit | CZK mil | 267 | ||||||
Staff Cost | CZK mil | 109 | ... | ... | ... | ... | ... | ... |
EBITDA | -28.9 | |||||||
Depreciation | CZK mil | 11.9 | ||||||
EBIT | -40.8 | |||||||
Net Financing Cost | CZK mil | 0.400 | ||||||
Financing Cost | CZK mil | 2.10 | ||||||
Financing Income | CZK mil | 1.40 | ||||||
FX (Gain) Loss | CZK mil | 0.300 | ||||||
Extraordinary Cost | CZK mil | -1.00 | ||||||
Pre-Tax Profit | CZK mil | -41.9 | ||||||
Tax | CZK mil | 0 | ||||||
Minorities | CZK mil | ... | ||||||
Net Profit | CZK mil | -41.9 | ||||||
Net Profit Avail. to Common | CZK mil | ... | ||||||
Dividends | CZK mil | 0 | ||||||
growth rates | ||||||||
Total Revenue Growth | % | 55.7 | ||||||
Operating Cost Growth | % | ... | ||||||
Staff Cost Growth | % | 61.1 | ... | ... | ... | ... | ... | ... |
EBITDA Growth | % | -340 | ||||||
EBIT Growth | % | -967 | ||||||
Pre-Tax Profit Growth | % | -1,781 | ||||||
Net Profit Growth | % | ... | ... | |||||
ratios | ||||||||
ROE | % | ... | ||||||
ROA | % | -15.1 | ||||||
ROCE | % | ... | ||||||
Gross Margin | % | 25.9 | ||||||
EBITDA Margin | % | -2.80 | ||||||
EBIT Margin | % | -3.95 | ||||||
Net Margin | % | -4.06 | ||||||
Payout Ratio | % | 0 | ||||||
Cost of Financing | % | ... | ||||||
Net Debt/EBITDA | -2.64 |
cash flow | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
cash flow | ||||||||
Net Profit | CZK mil | -41.9 | ||||||
Depreciation | CZK mil | 11.9 | ||||||
Non-Cash Items | CZK mil | 0.299 | ||||||
Change in Working Capital | CZK mil | 17.3 | ||||||
Total Cash From Operations | CZK mil | -13.4 | ||||||
Capital Expenditures | CZK mil | -33.4 | ||||||
Net Change in LT Investment | CZK mil | -3.75 | ||||||
Total Cash From Investing | CZK mil | -37.1 | ||||||
Dividends Paid | CZK mil | 0 | ||||||
Issuance Of Shares | CZK mil | 0 | ||||||
Issuance Of Debt | CZK mil | 42.5 | ||||||
Total Cash From Financing | CZK mil | 42.5 | ||||||
Effect of FX Rates | CZK mil | 0 | ||||||
Net Change In Cash | CZK mil | -8.05 | ||||||
ratios | ||||||||
Days Sales Outstanding | days | 59.3 | ||||||
Days Sales Of Inventory | days | 30.6 | ||||||
Days Payable Outstanding | days | 95.8 | ||||||
Cash Conversion Cycle | days | -5.91 | ||||||
Cash Earnings | CZK mil | -30.0 | ||||||
Free Cash Flow | CZK mil | -50.5 | ||||||
Capital Expenditures (As % of Sales) | % | 3.23 |
other ratios | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Employees | 217 | ... | ... | ... | ... | |||
Cost Per Employee | USD per month | 1,911 | ... | ... | ... | ... | ... | ... |
Cost Per Employee (Local Currency) | CZK per month | 41,811 | ... | ... | ... | ... | ... | ... |
Operating Cost (As % of Sales) | % | 28.7 | ||||||
Staff Cost (As % of Sales) | % | 10.5 | ... | ... | ... | ... | ... | ... |
Effective Tax Rate | % | 0 | ||||||
Total Revenue Growth (5-year average) | % | ... | ... | ... | ... | |||
Customers | mil | 0.239 |
valuation | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Market Capitalisation | USD mil | 40.1 | ||||||
Enterprise Value (EV) | USD mil | 43.5 | ||||||
Number Of Shares | mil | 1.00 | ||||||
Share Price | CZK | 900 | ||||||
EV/EBITDA | -32.9 | |||||||
Price/Earnings (P/E) | ... | |||||||
Price/Cash Earnings (P/CE) | -30.0 | |||||||
P/FCF | -17.8 | |||||||
Price/Book Value (P/BV) | 57.1 | |||||||
Dividend Yield | % | 0 | ||||||
Free Cash Flow Yield | % | -5.76 | ||||||
Earnings Per Share (EPS) | CZK | ... | ||||||
Cash Earnings Per Share | CZK | -30.0 | ||||||
Free Cash Flow Per Share | CZK | -50.5 | ||||||
Book Value Per Share | CZK | 15.8 | ||||||
Dividend Per Share | CZK | 0 | ||||||
EV/Sales | 0.920 | |||||||
EV/EBIT | -23.3 | |||||||
EV/Free Cash Flow | -18.8 | |||||||
EV/Capital Employed | 9.83 | |||||||
Earnings Per Share Growth | % | ... | ... | |||||
Cash Earnings Per Share Growth | % | ... | ||||||
Book Value Per Share Growth | % | ... | ||||||
Market Value per Customer | USD | 168 | ||||||
Sales per Customer | USD | 198 | ||||||
EBITDA per Customer | USD | -5.53 | ||||||
Net Profit per Customer | USD | -8.02 |
clients & arpu | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Customers | mil | 0.239 | ||||||
Customers (Czechia) | mil | 0.162 | ||||||
ARPU from Total Business | CZK per month | 361 |
Get all company financials in excel:
By Helgi Analytics - September 29, 2020
Pilulka made a net profit of CZK -58.5 mil with revenues of CZK 1,321 mil in 2019, down by 39.7% and up by 27.8%, respectively, compared to the previous year. This translates into a net margin of -4.43%. On the operating level, EBITDA reached CZK -36.4 mil,...
By Helgi Analytics - September 29, 2020
Pilulka made a net profit of CZK -58.5 mil with revenues of CZK 1,321 mil in 2019, down by 39.7% and up by 27.8%, respectively, compared to the previous year. This translates into a net margin of -4.43%. Historically, between 2018 and 2019, the firm...
By Helgi Analytics - September 29, 2020
Pilulka invested a total of CZK 33.8 mil in 2019, up 1.22% compared to the previous year. Historically, between 2018 - 2019, the company's investments stood at a high of CZK 33.8 mil in 2019 and a low of CZK 33.4 mil in 2018. As a per...
By Helgi Analytics - September 29, 2020
Pilulka's net debt stood at CZK 67.8 mil and accounted for 192% of equity at the end of 2019. The ratio is down 292 pp compared to the previous year. Historically, the firm’s net debt to equity reached a high of 484% in 2018 and a low of 192%...
By Helgi Analytics - September 29, 2020
Pilulka stock traded at CZK 900 per share at the end 2019 translating into a market capitalization of USD 40.1 mil. Since the end of 2014, the stock has appreciated by 0% representing an annual average growth of %. At the end of 2019, the firm traded at ...
By Helgi Analytics - September 29, 2020
Pilulka stock traded at CZK 900 per share at the end 2019 implying a market capitalization of USD 40.1 mil. Since the end of 2014, stock has appreciated by % implying an annual average growth of % In absolute terms, the value of the company rose by U...
Pilulka has been growing its sales by 26.4% a year on average in the last 5 years. EBITDA has grown by 504% during that time to total of 147 in 2024, or 3.44% of sales. That’s compared to 1.65% average margin seen in last five years.
The company netted CZK 82.3 mil in 2024 implying ROE of 31.8% and ROCE of 42.6%. Again, the average figures were -0.920% and 0.964%, respectively when looking at the previous 5 years.
Pilulka’s net debt amounted to CZK -60.8 mil at the end of 2024, or -20.6% of equity. When compared to EBITDA, net debt was -0.414x, down when compared to average of 0.808x seen in the last 5 years.
Pilulka stock traded at CZK 900 per share at the end of 2024 resulting in a market capitalization of USD 40.1 mil. Over the previous five years, stock price grew by 0% or 0% a year on average. The closing price put stock at a 12-month trailing EV/EBITDA of 5.56x and price to earnings (PE) of 11.5x as of 2024.